Skip to main content

Table 2 Adverse Events

From: A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

Toxicity All grades Grade 3 to 5
Docetaxel-sunitinib (N = 33) Docetaxel alone (N = 35) P value Docetaxel-sunitinib (N = 33) Docetaxel alone (N = 35) P value
All toxicities 84.8% 91.4% 0.400 30.3% 42.9% 0.285
Fatigue 30.3% 45.7% 0.145 6.1% 0% 0.232
Peripheral neuropathy 27.3% 31.4% 0.457 0% 2.9% 0.515
Diarrhoea 27.3% 25.7% 0.551 0% 0% NA
Neutropenia 24.2% 31.4% 0.509 18.2% 31.4% 0.207
Nausea 24.2% 22.9% 0.559 0% 0% NA
Anorexia 18.2% 20.0% 0.547 0% 0% NA
Vomiting 12.1% 14.3% 0.539 0% 0% NA
Fever 12.1% 11.4% 0.611 6.1% 11.4% 0.435
Cough 12.1% 8.6% 0.466 0% 0% NA
Xerostomia 12.1% 2.9% 0.160 0% 0% NA
Dizziness 12.1% 0% 0.050 0% 0% NA
Myalgia 9.1% 22.9% 0.112 0% 0% NA
Dyspnoea 6.1% 17.1% 0.149 0% 2.9% 0.515
Dyspepsia 6.1% 14.3% 0.239 0% 0% NA
Mouth ulcers 6.1% 11.4% 0.365 0% 0% NA
Insomnia 6.1% 8.6% 0.528 0% 0% NA
Hypersensitivity 6.1% 5.7% 0.670 0% 0% NA
Herpes Zoster 6.1% 2.9% 0.478 3.0% 0% 0.485
Sore throat 6.1% 2.9% 0.478 0% 0% NA
Dysgeusia 3.0% 5.7% 0.522 0% 0% NA
Lower limb oedema 3.0% 5.7% 0.522 0% 2.9% 0.515
\